[go: up one dir, main page]

MX2009003771A - Robust sustained release formulations. - Google Patents

Robust sustained release formulations.

Info

Publication number
MX2009003771A
MX2009003771A MX2009003771A MX2009003771A MX2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A MX 2009003771 A MX2009003771 A MX 2009003771A
Authority
MX
Mexico
Prior art keywords
sustained release
release formulations
formulations
robust
robust sustained
Prior art date
Application number
MX2009003771A
Other languages
Spanish (es)
Inventor
Anand R Baichwal
Steve Labudzinski
Kevin Fitzmaurice
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Publication of MX2009003771A publication Critical patent/MX2009003771A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these foϿnulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The formulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.
MX2009003771A 2006-10-10 2006-10-10 Robust sustained release formulations. MX2009003771A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/039923 WO2008045060A1 (en) 2006-10-10 2006-10-10 Robust sustained release formulations

Publications (1)

Publication Number Publication Date
MX2009003771A true MX2009003771A (en) 2009-07-22

Family

ID=38048029

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003771A MX2009003771A (en) 2006-10-10 2006-10-10 Robust sustained release formulations.

Country Status (10)

Country Link
EP (1) EP2079453A1 (en)
JP (1) JP5422388B2 (en)
KR (1) KR20090113243A (en)
CN (1) CN101578096A (en)
AU (1) AU2006349402A1 (en)
BR (1) BRPI0621947A2 (en)
CA (1) CA2652981C (en)
IL (1) IL198168A0 (en)
MX (1) MX2009003771A (en)
WO (1) WO2008045060A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004032A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
PL2456424T3 (en) 2009-07-22 2013-12-31 Gruenenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
ES2648129T3 (en) 2011-07-29 2017-12-28 Grünenthal GmbH Tamper-proof tablet that provides immediate release of a medication
PT2736495T (en) 2011-07-29 2017-11-30 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
TW201343201A (en) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd Sustained release oral solid preparation
AR090695A1 (en) 2012-04-18 2014-12-03 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM RESISTANT TO ADULTERATION AND RESISTANT TO IMMEDIATE RELEASE OF DOSE
KR20160031526A (en) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
AU2015266117A1 (en) * 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
CN108403651A (en) * 2015-02-13 2018-08-17 扬子江药业集团有限公司 dezocine oral preparation
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20170296476A1 (en) * 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
KR102380498B1 (en) * 2021-02-24 2022-04-01 주식회사 청안오가닉스 Composition for manufacturing sustained-release tablets capable of controlling sustained release of active ingredients in health functional food
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
FR2729857B1 (en) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SUSTAINED-RELEASE TABLETS BASED ON GRANULES OF HIGH MOLECULAR POLYSACCHARIDES
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
DZ3150A1 (en) * 1999-04-13 2000-10-19 Beecham Pharm Pte Ltd New treatment process.
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
WO2003004032A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
EP1404331B1 (en) * 2001-07-06 2007-10-31 Penwest Pharmaceuticals Co. Sustained release formulations of oxymorphone
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
WO2006094083A1 (en) * 2005-02-28 2006-09-08 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations

Also Published As

Publication number Publication date
JP5422388B2 (en) 2014-02-19
CN101578096A (en) 2009-11-11
AU2006349402A1 (en) 2008-04-17
KR20090113243A (en) 2009-10-29
WO2008045060A1 (en) 2008-04-17
JP2010505949A (en) 2010-02-25
EP2079453A1 (en) 2009-07-22
CA2652981A1 (en) 2008-04-17
IL198168A0 (en) 2009-12-24
BRPI0621947A2 (en) 2011-10-18
CA2652981C (en) 2012-05-01

Similar Documents

Publication Publication Date Title
MX2009003771A (en) Robust sustained release formulations.
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2007109057A3 (en) Solid dosage form containing a taste masked active agent
WO2007095600A3 (en) Disintegrable oral films
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
NO20070887L (en) Granular pharmaceutical formulation with time-limited release for oral administration, and intraoral rapid disintegrating tablet containing the preparation
WO2007103293A3 (en) Ethanol-resistant sustained release formulations
EP2248519A3 (en) Non-mucoadhesive film dosage forms
MX2010000803A (en) Formulations of nonopioid and confined opioid analgesics.
WO2010062688A3 (en) Dosage form for insertion into the mouth
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
NZ592276A (en) PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(epsilon-CAPROLACTONE) AND AN OPIOID
MX2008000099A (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof.
UA104745C2 (en) Tamper resistant oral pharmaceutical dosage form comprising an opioid analgesic
IL220722A (en) Use of fentanyl in the preparation of a pharmaceutical composition for providing rapid onset of relief from breakthrough pain and a mucoadhesive bioerodable drug delivery device suitable for direct transmucosal administration of fentanyl
ATE474564T1 (en) SMALL VOLUME, ORAL, TRANSMUCOSAL DOSAGE FORMS OF SUFENTANIL FOR PAIN TREATMENT
IL179896A (en) Opioid sustained release oral dosage form comprising a mixture of an opioid agonist and an opioid antagonist for use in the treatment of restless leg syndrome
JP2009522376A5 (en)
WO2007106550A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
NZ628513A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
MX2009009132A (en) Improved medicinal compositions comprising buprenorphine and naltrexone.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2007123865A3 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
MX2009003770A (en) Robust sustained release formulations of oxymorphone and methods of use thereof.